Drug intelligence / Profile preview

AJU-C714

Development stage: Phase 1
Lead developer: AJU Pharm
Modality: Small Molecules
Administration: Oral

Overview

**AJU-C714** is an investigational antihyperlipidaemic drug developed by AJU Pharm for the treatment of dyslipidemia. It is classified as a new molecular entity and is currently in Phase 1 clinical development in South Korea. Details regarding its mechanism of action and molecular target are currently undefined in publicly available sources, indicating either a novel or undisclosed pathway. No orphan drug status has been assigned and there is no information on its use for other indications or its active ingredient[1][3][4][5][9][10].

Brand names: AJU-C714AJU-C-714AJU-C 714
Other names: AJU-C714AJU-C-714AJU-C 714

Beyond the preview

Go deeper on AJU-C714.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AJU-C714.

Explore the full profile